479079-15-7

Basic information

• Product Name: Carbamic acid, [2-(hydroxyamino)-2-iminoethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [2-(hydroxyamino)-2-iminoethyl]-, 1,1-dimethylethyl ester (9CI);MFCD20441218;N-[(2Z)-2-amino-2-hydroximino-ethyl]carbamic acid tert-butyl ester;N-[(2Z)-2-amino-2-hydroxyiminoethyl]carbamic acid tert-butyl ester;tert-butyl [(2E)-2-amino-2-(hydroxyimino)ethyl]carbamate;tert-butyl N-[(2Z)-2-amino-2-hydroxyiminoethyl]carbamate;tert-butyl N-[(2Z)-2-amino-2-hydroxyimino-ethyl]carbamate;tert-Butyl (2-(hydroxyamino)-2-iminoethyl)carbamate
• CAS NO: 479079-15-7
• Molecular Formula: C₇H₁₅N₃O₃
• Molecular Weight: 189.2123
• Product Categories: N-BOC
• Mol File: 479079-15-7.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Carbamic acid, [2-(hydroxyamino)-2-iminoethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(hydroxyamino)-2-iminoethyl]-, 1,1-dimethylethyl ester (9CI)(479079-15-7)
• EPA Substance Registry System: Carbamic acid, [2-(hydroxyamino)-2-iminoethyl]-, 1,1-dimethylethyl ester (9CI)(479079-15-7)

Safety Data

• Hazardous Substances Data: 479079-15-7(Hazardous Substances Data)

Upstream product

• 4530-20-5 BOC-glycine 
• 35150-09-5 N-(tert-butoxycarbonyl)glycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 85363-04-8 tert-butyl cyanomethylcarbamate 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 612511-76-9 3-(tert-butoxycarbonylamino-methyl)-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester 
• 1364677-67-7 C-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-methylamine hydrochloride 
• 1058148-48-3 C₂₁H₃₀N₄O₅ 

Relevant articles and documents

Exploring Heteroaromatic Rings as a Replacement for the Labile Amide of Antiplasmodial Pantothenamides

Malaria-causing Plasmodium parasites are developing resistance to antimalarial drugs, providing the impetus for new antiplasmodials. Although pantothenamides show potent antiplasmodial activity, hydrolysis by pantetheinases/vanins present in blood rapidly inactivates them. We herein report the facile synthesis and biological activity of a small library of pantothenamide analogues in which the labile amide group is replaced with a heteroaromatic ring. Several of these analogues display nanomolar antiplasmodial activity against Plasmodium falciparum and/or Plasmodium knowlesi, and are stable in the presence of pantetheinase. Both a known triazole and a novel isoxazole derivative were further characterized and found to possess high selectivity indices, medium or high Caco-2 permeability, and medium or low microsomal clearance in vitro. Although they fail to suppress Plasmodium berghei proliferation in vivo, the pharmacokinetic and contact time data presented provide a benchmark for the compound profile likely required to achieve antiplasmodial activity in mice and should facilitate lead optimization.

Preparation method and intermediate of benzodiazepine compound

The invention discloses a preparation method of a benzodiazepine compound and an intermediate compound K. The compound K disclosed by the invention can be used for preparing the compound shown as theformula I in one step at high yield. The preparation met

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.